Cargando…

Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells

BACKGROUND: Cytotoxic anticancer drugs widely used in cancer chemotherapy have some limitations, such as the development of side effects and drug resistance. Furthermore, monotherapy is often less effective against heterogeneous cancer tissues. Combination therapies of cytotoxic anticancer drugs wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishikubo, Kou, Ohgaki, Ryuichi, Liu, Xingming, Okanishi, Hiroki, Xu, Minhui, Endou, Hitoshi, Kanai, Yoshikatsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268460/ https://www.ncbi.nlm.nih.gov/pubmed/37322479 http://dx.doi.org/10.1186/s12935-023-02957-z

Ejemplares similares

Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells
por: Nishikubo, Kou, et al.
Publicado: (2022)

Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor
por: Okanishi, Hiroki, et al.
Publicado: (2020)

Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of l-type amino acid transporter 1
por: Okanishi, Hiroki, et al.
Publicado: (2022)

Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models
por: Shi, Zitong, et al.
Publicado: (2023)

Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation
por: Quan, Lili, et al.
Publicado: (2020)

Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB(0,+), LAT1 and LAT2
por: Wongthai, Printip, et al.
Publicado: (2015)

Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With α-Alkyl Moieties
por: Khunweeraphong, Narakorn, et al.
Publicado: (2012)

Specific transport of 3‐fluoro‐l‐α‐methyl‐tyrosine by LAT1 explains its specificity to malignant tumors in imaging
por: Wei, Ling, et al.
Publicado: (2016)

A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy
por: Jimbo, Keisuke, et al.
Publicado: (2020)

Correction: A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy
por: Jimbo, Keisuke, et al.
Publicado: (2021)

Inhibition of the amino‐acid transporter LAT1 demonstrates anti‐neoplastic activity in medulloblastoma
por: Cormerais, Yann, et al.
Publicado: (2019)

LAT1 expression influences Paneth cell number and tumor development in Apc(Min/+) mice
por: Sui, Yunlong, et al.
Publicado: (2023)

Correction: LAT1 expression influences Paneth cell number and tumor development in Apc(Min/+) mice
por: Sui, Yunlong, et al.
Publicado: (2023)

Structural insights into inhibitory mechanism of human excitatory amino acid transporter EAAT2
por: Kato, Takafumi, et al.
Publicado: (2022)

JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells
por: Choi, Dae Woo, et al.
Publicado: (2017)

Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor
por: Rii, Junryo, et al.
Publicado: (2021)

Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma
por: Isoda, Atsushi, et al.
Publicado: (2014)

Significance of System L Amino Acid Transporter 1 (LAT-1) and 4F2 Heavy Chain (4F2hc) Expression in Human Developing Intestines
por: Ohno, Chikara, et al.
Publicado: (2009)

Ratiometric fluorescence imaging of cell surface pH by poly(ethylene glycol)-phospholipid conjugated with fluorescein isothiocyanate
por: Ohgaki, Ryuichi, et al.
Publicado: (2017)

The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
por: Cormerais, Yann, et al.
Publicado: (2018)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2022)

MON-470 Pharmacological Inhibition of LAT1 Suppresses Proliferation and Hormone Synthesis in Rat Pituitary Tumor GH4 Cells [cc1] Synthesis May Be Better as Only mRNAs Were Measured
por: Sato, Motoyasu, et al.
Publicado: (2019)

α‐Emitting cancer therapy using (211)At‐AAMT targeting LAT1
por: Kaneda‐Nakashima, Kazuko, et al.
Publicado: (2021)

NRFL-1, the C. elegans NHERF Orthologue, Interacts with Amino Acid Transporter 6 (AAT-6) for Age-Dependent Maintenance of AAT-6 on the Membrane
por: Hagiwara, Kohei, et al.
Publicado: (2012)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)
por: Fujiwara, Yutaka, et al.
Publicado: (2015)

Role of L-Type Amino Acid Transporter 1 (LAT1) for the Selective Cytotoxicity of Sesamol in Human Melanoma Cells
por: Srisongkram, Tarapong, et al.
Publicado: (2019)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Small molecule inhibitors provide insights into the relevance of LAT1 and LAT2 in materno‐foetal amino acid transport
por: Zaugg, Jonas, et al.
Publicado: (2020)

Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties
por: Kawakami, Koji, et al.
Publicado: (2006)

Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles
por: Popescu, Roxana Cristina, et al.
Publicado: (2017)

Yeast Cell-Based Transport Assay for the Functional Characterization of Human 4F2hc-LAT1 and ‐LAT2, and LAT1 and LAT2 Substrates and Inhibitors
por: Kantipudi, Satish, et al.
Publicado: (2021)

Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors
por: Barollo, Susi, et al.
Publicado: (2016)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Evaluation of LATS1 and LATS2 Promoter Methylation with the Risk of Pterygium Formation
por: Najafi, Maryam, et al.
Publicado: (2016)

Gemcitabine-incorporated polyurethane films for controlled release of an anticancer drug
por: Choi, Seong Hoon, et al.
Publicado: (2019)

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
por: Fraunhoffer, Nicolas Alejandro, et al.
Publicado: (2022)

Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report
por: Nishikubo, Masashi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1fi8uol0jlk6phjcvah305n87t